Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amicus Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant had completed treatment in a previous study of migalastat HCl given as a monotherapy
Male and female participant agreed to use protocol-identified acceptable contraception
Participant was willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI)
You may not be if
Participant's last available estimated glomerular filtration rate (eGFR) in the previous study was \<30 milliliter (mL)/minute (min)/1.73 meters squared (m\^2); unless there was measured GFR available within 3 months of Baseline Visit, which was \>30 mL/min/1.73 m\^2
Participant had undergone, or was scheduled to undergo kidney transplantation or was currently on dialysis
Participant had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Baseline Visit
Participant had clinically significant unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)
Participant had a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (for example, miglustat, miglitol)
Participant required treatment with Glyset® (miglitol) or Zavesca® (miglustat)
Participants with severe or unsuitable concomitant medical condition
